Skip to content
Search

Latest Stories

PDA urges GPhC to ensure a fair assessment process for provisionally registered pharmacists

The Pharmacists' Defence Association (PDA) has raised its concerns over Pearson VUE’s ability to deliver an efficient and fair examination process for provisionally registered pharmacists and re-sitters next year.

Assessment exam of the provisionally registered pharmacists and re-sitters was cancelled this year due to the Covid-19 pandemic.


The PDA has called on the General Pharmaceutical Council (GPhC) to ensure that every step is taken to develop, deliver and adequately test the process before the exam.

“This is to ensure that there is a 'fit for purpose' online registration assessment that not only provides the public with the confidence in the next generation of pharmacists but also gives candidates a fair test opportunity to apply their knowledge and skills without further detriment,” the PDA has said.

The Pearson Vue, the company which provides online academic and government testing programmes, has come under criticism over their handling of other professional body online examination processes including the 2020 pharmacy examinations in Australia.

“Key issues have been reported around examination platform performance, reasonable adjustments for those with disabilities and issues with the management of online booking and log in processes,” the PDA added.

“During a PDA meeting with members, a number of issues and questions were raised which we have submitted to the regulator to help inform the development of their FAQs for the future assessment. In addition, we have raised our member’s concerns about the reported experiences of other professionals who have recently sat online examinations provided by Pearson Vue contracts,” it added.

Reassurance from  GPhC

Meanwhile, the GPhC has reassured that it will work closely with Pearson Vue to deliver a fair and efficient examination process.

Mark Voce, GPhC director of education and standards, said: "I’d like to reassure candidates that we are listening very carefully to all of the concerns and questions they are raising and taking them into account when developing the plans for the next sitting of the registration assessment.

“We are working closely with Pearson Vue to make sure our requirements for the registration assessment are met and it is robust and fair for candidates. We will be sending a further update to candidates before the end of November.”

The cohort of provisionally registered pharmacists and re-sitters have already experienced unprecedented levels of change and challenges and many have worked tirelessly, contributing to the pharmacy sector's response to Covid-19.

These new professionals will also be expected to play their part during the Covid-19 vaccination programme.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less